Last reviewed · How we verify

NCT00092573

Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia

Completed Phase 3 Last updated 12 August 2024
What this trial tests

Phase 3 trial testing MK0653, ezetimibe in Hypercholesterolemia in 576 participants. Completed in 1 November 2004.

Timeline
1 April 2003
Primary endpoint
1 November 2004
1 November 2004

Quick facts

Lead sponsorOrganon and Co
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Primary purposetreatment
Enrollment576
Start date1 April 2003
Primary completion1 November 2004
Estimated completion1 November 2004

Drugs / interventions tested

Conditions studied

Sponsor

Organon and Co — full company profile →

Who can join

Adults 18 to 75, any sex, with Hypercholesterolemia or Hypertriglyceridemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to assess the cholesterol lowering safety and effectiveness of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MK0653, ezetimibe

Trials testing the same drug.

Other recruiting trials for Hypercholesterolemia

Currently open trials in the same condition.

Other Organon and Co trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00092573.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing